



Cascadian Therapeutics
Investor Relations Department
2601 4th Avenue, Suite 500
Seattle, WA 98121
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: CASC

| | |
|---------------|--|
| Last Trade: | 4.32 |
| Trade Time: | 4:00 PM ET Oct 20, 2017 |
| Change: | 0.21  (+5.109%) |
| Day Range | 4.11 - 4.35 |
| 52-Week Range | 3.18 - 7.80 |
| Volume | 228,344 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please [contact](#) us.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 27, 2017

[Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer](#)

Sep 20, 2017

[Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)

Sep 11, 2017

[Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology \(ESMO\) 2017 Congress](#)

Sep 11, 2017

[Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology \(ESMO\) 2017 Congress](#)

Aug 28, 2017

[Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology \(ESMO\) 2017 Congress](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 9, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)